What Is Inspire Sleep Apnea Treatment?

Inspire is a prescription implant that treats obstructive sleep apnea (OSA) in carefully selected people. It senses the timing of breathing and sends electrical stimulation to the hypoglossal nerve, which helps move the tongue forward as a person inhales. This can reduce upper-airway collapse without a mask or hose ¹.

Inspire is not a cure for OSA, and it does not treat every type of sleep apnea. It is not a heart pacemaker, even though people sometimes call it a “tongue pacemaker.” It does not regulate the heart, and it is not intended for people whose breathing events are predominantly central rather than obstructive ¹.

The implant is only one part of treatment. Surgery is followed by healing, activation, gradual adjustment, clinician programming and a sleep study to measure the result. Some people have substantial improvement, some have residual OSA, and some do not meet the usual definition of a treatment response.

How Inspire works

The hypoglossal nerve controls muscles that move the tongue. During sleep, Inspire times stimulation to inspiration so that tongue movement helps create more space in the upper airway. A clinician programs the stimulation, sensing and timing settings. The person uses a remote to turn therapy on before sleep and off after waking, pause it, and adjust stimulation only within limits set by the clinician ².

The implanted parts depend on the device model:

• Model 3028 systems use a generator under the upper-chest skin, a stimulation lead with a cuff around a branch of the hypoglossal nerve, and a separate sensing lead that detects breathing.
• Model 3150 systems use a generator that senses inspiration itself plus a stimulation lead, so there is no separate respiratory sensing lead ².

The number and location of incisions can therefore differ by model and surgical plan. A remote and clinician programmer are external parts of the system. The device responds to the breathing signal, but it does not independently decide whether the airway is adequately treated. Follow-up testing is still needed.

Who may qualify under the current U.S. label

The FDA-approved indication below is current as of July 26, 2026. It is broader than many older descriptions of Inspire, which may still quote an AHI limit of 65, a BMI limit of 32 or 35, or adult-only use ¹².

Age or group	Current labeled requirements
Age 22 or older	Moderate to severe OSA with an AHI from 15 through 100, PAP failure or intolerance, and no complete concentric collapse at the soft palate
Ages 18 to 21	AHI from 15 through 100, no complete concentric collapse, adenotonsillectomy contraindicated or ineffective, PAP failure or intolerance despite attempts to improve use, and consideration of other standard alternatives or add-on treatments
Ages 13 to 18 with Down syndrome	AHI from 10 through 50, plus the same palate, adenotonsillectomy, PAP and alternative-treatment requirements

In the labeling, PAP failure means OSA remains inadequately controlled, with an AHI above 15 despite PAP use. PAP intolerance includes being unable to use PAP for more than five nights each week, with use defined as more than four hours per night, or being unwilling to continue after a genuine attempt, such as returning the device ². These definitions help determine implant eligibility. They are not instructions to stop PAP without the treating team.

BMI is an evidence boundary, not a simple yes-or-no rule

The FDA expanded its recommended upper BMI warning from 32 to 40 in 2023. Current labeling says that safety and effectiveness above a BMI of 40 are unknown because that population has not been studied in meaningful numbers. It does not list BMI above 40 as a stand-alone contraindication. For young people with Down syndrome, BMI above the 95th percentile on the CDC neurotypical growth curves has not been studied ¹².

In the ADHERE registry analysis, lower baseline BMI predicted a greater chance of meeting the study's AHI response definition ³. Coverage policies and implant programs may also use narrower rules than the FDA label. As checked on July 26, 2026, one Medicare local coverage policy uses age 22 or older, BMI below 35 and AHI from 15 through 65 ⁴. That is a coverage rule, not the current FDA indication.

Important contraindications

The current label lists several reasons the system should not be used ¹²:

• Central and mixed apneas together make up more than 25% of the total AHI.
• Complete concentric collapse of the soft palate or another anatomical finding would compromise stimulation.
• A condition or prior procedure has compromised neurological control of the upper airway.
• The person cannot operate the remote and does not have reliable help to do so.
• The person is pregnant or plans to become pregnant.
• Another implant may interact with the Inspire system and the device manufacturers have not established compatibility.
• The person needs MRI scans outside the conditions allowed for the exact implanted system.
• The person has rhabdomyolysis.

Meeting the label does not guarantee that implantation is appropriate. Medical conditions, anatomy, expected benefit, surgery and anesthesia risk, ability to complete follow-up and personal preferences all matter.

What the screening process should establish

A proper evaluation usually involves both sleep medicine and an implanting surgeon. It should answer several separate questions:

1. Is the diagnosis predominantly obstructive? A current sleep study should establish the AHI, oxygen pattern and proportion of obstructive, central and mixed events.
2. Has PAP genuinely failed or remained intolerable? The team should review PAP data and address fixable problems such as mask fit, dryness, pressure discomfort or inadequate follow-up before concluding that PAP is not workable.
3. Is the airway pattern suitable? Drug-induced sleep endoscopy, or DISE, lets a surgeon view the airway during sedation. It is commonly used to document the absence of complete concentric soft-palate collapse, and some coverage policies specifically require it ⁴.
4. Are there device or procedure conflicts? The team needs to know about implanted cardiac or neurological devices, future MRI needs, pregnancy plans, relevant neurological conditions and the person's ability to use the remote.
5. Are expectations realistic? The goal is meaningful control of OSA, not guaranteed elimination of every event, snoring or daytime symptom.

DISE is not a general test of whether someone “passes” surgery. It answers an anatomy question that cannot be settled from AHI or BMI alone.

Surgery, activation and nightly use

Implantation is performed under anesthesia. The surgeon places the generator and stimulation lead, plus a respiratory sensing lead when the selected model requires one. The exact incision plan, same-day discharge decision, pain plan and activity restrictions depend on the model, procedure and individual health.

The current Model 3150 manual recommends an incision check after about 7 to 14 days. It notes that incision discomfort may last two to six weeks and that bending, twisting and large arm movements may need to be limited for several weeks while the system heals in place. The surgeon's instructions take priority over a general timeline ².

The system is not normally used on the night of surgery. The manufacturer's current pathway is:

1. Healing: Therapy remains off while the incisions and implanted components settle.
2. Activation: The manual recommends activation at about four weeks. The clinician programs an initial range and teaches remote use.
3. Acclimation: Stimulation may be increased gradually within the clinician-set plan. Comfort does not prove that the dose is effective.
4. Titration and confirmation: The manual calls for at least one sleep study about four to eight weeks after activation. More programming or another study may be needed ².
5. Ongoing follow-up: The team reviews comfort, usage, symptoms, device status and objective OSA control over time.

Each night, the user turns therapy on before sleep. A programmed delay allows time to fall asleep. The remote can pause therapy and, when enabled, adjust amplitude only within the clinician-defined range ². Persistent discomfort, tongue symptoms, repeated awakenings or a return of OSA symptoms should prompt a call to the treating team rather than repeated unsupervised changes.

How effective is Inspire?

Inspire can substantially reduce OSA severity in selected patients, but the result is not uniform. The often-quoted “68% reduction” describes a group median from the original pivotal trial. It does not mean that every user improves by 68%, nor that 68% are cured.

Evidence	Main result	What limits the conclusion
STAR pivotal study, 126 implanted adults	Median AHI fell from 29.3 to 9.0 events per hour at 12 months, a 68% reduction. A randomized withdrawal phase in selected responders showed AHI worsening when stimulation was stopped 5.	The main 12-month comparison was an uncontrolled before-and-after cohort, 83% of participants were men, mean BMI was 28.4, and the study was funded by Inspire. The population was narrower than the current label.
STAR five-year follow-up	Among 71 people who volunteered for a five-year sleep study, 75% met the study response definition of at least a 50% AHI reduction and an AHI below 20. A last-observation-carried-forward analysis gave a 63% response rate. Serious device-related events involving lead or device adjustment were reported in 6% 6.	Only 71 of the original 126 had the voluntary five-year sleep study. Attrition and selection can make the observed responder percentage look better than a full-cohort estimate.
ADHERE clinical registry	Among 382 participants with 12-month follow-up in one analysis, median AHI fell from 32.8 to 9.5 and mean recorded use was 5.6 hours per night. Sleepiness scores also improved on average 3.	This was an observational registry without a randomized comparison. Only part of the 1,017 enrolled participants had reached 12-month follow-up for that report.
Adolescents with Down syndrome	In a referred single-group cohort of 42 adolescents, mean AHI fell by 12.9 events per hour at one year. Of 41 with outcome data, 65.9% had at least a 50% reduction and 73.2% had an AHI below 10. Two participants had reoperations 7.	This small study had no control group and involved a highly selected population with persistent severe OSA after adenotonsillectomy and PAP intolerance. It does not apply to children without Down syndrome.

The FDA's 2023 expansion to AHI values through 100 and the higher BMI warning relied largely on retrospective ADHERE data. The AHI analysis included 31 people with baseline AHI above 65 through 75 and 26 with AHI above 75 through 100; the BMI analysis included 279 people above 32 through 40 ¹². These data supported broader labeling, but they are less mature than evidence for the original, narrower trial population.

An AHI response is not the same as remission. A person whose AHI falls from 50 to 18 has a large response but still has OSA. Recorded nightly use shows that the system was turned on; it does not establish that breathing, oxygen and symptoms are controlled. The follow-up sleep study and clinical review provide that information.

Risks, side effects and long-term tradeoffs

Inspire combines the risks of surgery, an implanted electronic system and nightly nerve stimulation. Current labeling lists the following possibilities ²:

Area	Possible problems
Surgery and implant pocket	Bleeding, blood-vessel injury, infection, swelling, seroma, hematoma, skin erosion, allergic or rejection response, persistent pain, numbness, inflammation, scarring and pneumothorax
Nerve, tongue and throat	Nerve injury, tongue soreness, abrasion, weakness, restricted movement, paresis or atrophy, swallowing or speech problems, coughing, choking and dry mouth
Stimulation and sleep	Uncomfortable or unwanted stimulation, insomnia, arousals, headache and changes in stimulation as tissue or lead position changes
Hardware	Lead movement or fracture, loose connections, loss of therapy, generator or lead discomfort, revision, replacement or explant surgery
Removal	Scar tissue can make complete lead removal difficult or unsafe. Part of a lead may need to remain, which can change future MRI eligibility.

Severe breathing difficulty, chest pain, rapidly increasing neck or chest swelling, fainting or another acute severe symptom after surgery needs emergency assessment. Fever, spreading redness, drainage, worsening incision pain, new marked tongue weakness or persistent swallowing and speech difficulty should be reported promptly to the surgical team.

Battery and future surgery

The generator battery is not rechargeable. For the current Model 3150, the manufacturer estimates average longevity of 10.9 years and a minimum estimate of seven years, while stating that actual longevity depends on settings and use ². Other models and individual settings differ. When the generator reaches its replacement window, another procedure is needed. Lead problems, infection, loss of effect or discomfort can also lead to revision or removal before battery depletion.

MRI and other implanted devices

“MRI compatible” is too broad. The exact generator, leads, implant location, system condition, scanner strength, coil and scan protocol all matter.

• Model 3024 generators are not eligible for MRI.
• Model 3028 and Model 3150 systems are MR Conditional, which means scanning is permitted only under the conditions in the current manufacturer guide. The March 2026 guide includes defined 1.5-tesla and 3-tesla pathways, including certain whole-body and local-coil scans. It does not support the old blanket claim that every chest or torso MRI is prohibited ⁸.
• The implant card should be used to identify the components. Therapy must be off for the scan, and the remote must not enter the MRI scanner room ⁸.

Tell every medical, dental and imaging clinician about the implant. Diathermy is prohibited because it can injure tissue or damage the system, and the current Model 3150 manual says to avoid transcranial magnetic stimulation ². Another implanted device, including a cardiac device, requires an interaction assessment by the treating teams and device manufacturers. Compatibility should never be assumed from the device category alone.

If Inspire is not suitable or does not fully control OSA

Inspire is one option within a broader OSA plan. The appropriate alternative depends on the type and severity of apnea, anatomy, symptoms, medical conditions and treatment history.

• Revisit PAP: Mask refitting, humidification, pressure-related troubleshooting, education and close follow-up can make PAP more usable. PAP remains an effective treatment and should have adequate follow-up to confirm benefit and use ⁹.
• Consider a custom oral appliance: For an adult who is intolerant of CPAP or prefers an alternative, guidelines support considering a custom, titratable appliance fitted and monitored by a qualified dentist, with follow-up sleep testing ¹⁰.
• Discuss other sleep-surgery options: AASM guidance recommends discussing referral to a sleep surgeon with adults who have OSA, a BMI below 40 and intolerance or unwillingness to use PAP, while emphasizing individualized risks, anatomy and preferences ¹¹.
• Address relevant contributors: Weight-management care, positional therapy for position-dependent OSA, treatment of nasal obstruction and anatomy-directed surgery may be part of an individual plan. None should be assumed to replace objective follow-up.
• Use a separate central-apnea pathway: Inspire is not a substitute for cause-specific evaluation and treatment of central sleep apnea.

Do not stop PAP or another effective OSA treatment merely because implantation is scheduled. The implant is inactive during initial healing, and its effectiveness remains unknown until activation, titration and follow-up testing. The treating sleep team should decide when an existing treatment can be reduced or stopped.

Persistent sleepiness remains a safety issue even if snoring improves. If you are fighting sleep while driving or have had a sleepiness-related near miss, do not drive until the risk has been assessed and effectively managed. The American Thoracic Society recommends prompt evaluation and treatment for people at high driving risk from suspected or confirmed OSA ¹².

Questions to ask before deciding

A useful consultation should give clear answers to these questions:

• Which exact generator and lead configuration is planned, and why?
• Which parts of my sleep study show that my apnea is predominantly obstructive?
• How was PAP failure or intolerance established, and are there remaining PAP problems worth fixing?
• What did DISE show about my palate, tongue base and other sites of collapse?
• Do I meet the current FDA label, the implant center's criteria and my coverage criteria?
• How closely do my AHI, BMI, age and health match the populations with the strongest outcome data?
• What are this surgeon's incision, recovery and complication expectations for the planned model?
• When will activation, titration and objective follow-up testing occur?
• What result would count as adequate control, and what is the plan if significant OSA remains?
• How will the system affect MRI, other implanted devices, future procedures and generator replacement?

Inspire can be a useful OSA treatment when the diagnosis, anatomy, PAP history and long-term follow-up all fit. A reasonable decision weighs the expected benefit, evidence uncertainty, surgery and lifelong device management for one specific person.